These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34580375)

  • 1. In vitro and in vivo comparative study of a novel
    Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
    Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Linker Modification on Tumor-to-Kidney Contrast of
    Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
    [No Abstract]   [Full Text] [Related]  

  • 3. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
    Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
    Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties.
    Hou H; Pan Y; Wang Y; Ma Y; Niu X; Sun S; Hou G; Tao W; Gao F
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2819-2832. PubMed ID: 38683349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
    Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
    Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M
    J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
    Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
    Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
    J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
    Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel [
    Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF
    Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihormone treatment differentially regulates PSA secretion, PSMA expression and
    Mathy CS; Mayr T; Kürpig S; Meisenheimer M; Dolscheid-Pommerich RC; Stoffel-Wagner B; Kristiansen G; Essler M; Muders MH; Bundschuh RA
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1733-1743. PubMed ID: 33760944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.